Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Burden and outcomes of CAR T-cell therapy toxicities in DLBCL, multiple myeloma, and B-ALL: A nationwide analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

PKPraneeth Reddy Keesari

Discussion

Loading...

Member takes

Overview

Nationwide analysis shows CAR T-cell therapy toxicities in DLBCL, multiple myeloma, and B-ALL, suggesting significant complications and economic burdens.

Key Points

  • This research investigates the toxicities associated with CAR T-cell therapy in various blood cancers.
  • Analyzed Nationwide Inpatient Sample database from 2020 to 2022.
  • Identified hospitalizations for adults receiving CAR-T therapy for DLBCL, multiple myeloma, or B-ALL.
  • Examined inpatient outcomes, including mortality, acute renal failure, complications like CRS and ICANS.
  • Performed statistical analyses using Stata 18.5 with multivariable logistic regression.
  • Identified 10,650 CAR-T recipients: DLBCL 46.5%, MM 19.6%, and B-ALL 10.9%.
  • Inpatient mortality rates were 2.8% for DLBCL, 3.0% for B-ALL, and 3.8% for MM.
  • CRS was observed in 47.1% of patients, highest in MM at 53.96%.
  • ARF rates were highest in MM at 21.6%, significantly higher than DLBCL and B-ALL.

Cite This Study

Praneeth Reddy Keesari (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d049https://doi.org/10.1182/blood-2025-8131
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Beyond the trial: Real-world CRS, icans, and healthcare burden of CAR T-cell therapy across US oncology practices2025 · 1 citations
  2. 2Real-world comparative outcomes of CAR-T cell therapy versus bispecific antibodies in patients with diffuse large B-cell lymphoma2025
  3. 3Real-world comparison of CAR T-cell therapy versus bispecific antibodies in relapsed or refractory multiple myeloma2025 · 1 citations
  4. 4Risk of second primary malignancy following chimeric antigen receptor T-cell therapy: A real-world cohort study2025 · 1 citations
  5. 5Cytopenias and infectious complications following CD19-directed CAR-T cell therapy in patients with B-ALL: A single-center retrospective analysis2025